English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/183896
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Brain Innate Immunity in the Regulation of Neuroinflammation: Therapeutic Strategies by Modulating CD200-CD200R Interaction Involve the Cannabinoid System

AuthorsHernangómez-Herrero, Miriam ; Carrillo-Salinas, Francisco; Mecha, Miriam ; Correa, Fernando Gabriel ; Mestre, Leyre ; Loría, Frida ; Feliú, Ana; Docagne, Fabian ; Guaza, Carmen
KeywordsNeuroinflammation
Microglia
Neurons
Neuroimmunoregulatory molecules
CD200
CD200R
Multiple sclerosis
Aging brain
Alzheimer’s disease
Cannabinoids
Issue Date2014
PublisherBentham Science Publishers
CitationCurrent Pharmaceutical Design 20(29): 4707-4722 (2014)
AbstractThe central nervous system (CNS) innate immune response includes an arsenal of molecules and receptors expressed by professional phagocytes, glial cells and neurons that is involved in host defence and clearance of toxic and dangerous cell debris. However, any uncontrolled innate immune responses within the CNS are widely recognized as playing a major role in the development of autoimmune disorders and neurodegeneration, with multiple sclerosis (MS) Alzheimer's disease (AD) being primary examples. Hence, it is important to identify the key regulatory mechanisms involved in the control of CNS innate immunity and which could be harnessed to explore novel therapeutic avenues. Neuroimmune regulatory proteins (NIReg) such as CD95L, CD200, CD47, sialic acid, complement regulatory proteins (CD55, CD46, fH, C3a), HMGB1, may control the adverse immune responses in health and diseases. In the absence of these regulators, when neurons die by apoptosis, become infected or damaged, microglia and infiltrating immune cells are free to cause injury as well as an adverse inflammatory response in acute and chronic settings. We will herein provide new emphasis on the role of the pair CD200-CD200R in MS and its experimental models: experimental autoimmune encephalomyelitis (EAE) and Theiler’s virus induced demyelinating disease (TMEV-IDD). The interest of the cannabinoid system as inhibitor of inflammation prompt us to introduce our findings about the role of endocannabinoids (eCBs) in promoting CD200-CD200 receptor (CD200R) interaction and the benefits caused in TMEV-IDD. Finally, we also review the current data on CD200-CD200R interaction in AD, as well as, in the aging brain.
Publisher version (URL)https://doi.org/10.2174/1381612820666140130202911
URIhttp://hdl.handle.net/10261/183896
DOI10.2174/1381612820666140130202911
ISSN1381-6128
E-ISSN1873-4286
Appears in Collections:(IC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf59,24 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.